鷹瞳科技-B(2251.HK)今日掛牌上市
格隆匯11月5日丨鷹瞳科技-B(2251.HK)今日首日在港掛牌上市,IPO價格為75.1港元/股,此次上市淨籌15.664億港元。鷹瞳科技是全球視網膜影像人工智能領域的領導者和先行者。公司擁有基於視網膜影像人工智能識別的早期檢測、輔助診斷及健康風險評估解決方案,能夠通過視網膜影像、多模態數據分析及人工智能深度學習算法,改善了慢性病傳統的早期檢測及診斷方式,在醫療機構和大健康場景中實現對慢性病的無創、精確、快速、高性價比的相關健康風險評估。招股書顯示,2019年、2020年以及2021年上半年,鷹瞳科技營收分別為3041.5萬元、4767.2萬元、4947.7萬元,僅2021年上半年收入已全面超過了2020年全年,同比增長660%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.